Benzinga | Aug 11, 2021 04:28PM EDT

ADMA Biologics Q2 EPS ~$(0.15), Inline, Sales ~$17.80M Beat $16.42M Estimate

ADMA Biologics (NASDAQ:ADMA) reported quarterly losses of $(0.15) per share which met the analyst consensus estimate. This is a 34.78 percent increase over losses of $(0.23) per share from the same period last year. The company reported quarterly sales of $17.80 million which beat the analyst consensus estimate of $16.42 million by 8.40 percent. This is a 128.56 percent increase over sales of $7.79 million the same period last year.